Niraparib is an orally active poly (ADP-ribose) polymerase (PARP) inhibitor. By blocking the enzymes responsible for DNA repair, niraparib induces cytotoxicity in cancer cells.[L43277] Niraparib is selective towards PARP-1 and PARP-2.[A253248] First approved by the FDA on March 27, 2017,[A253912] niraparib is used to treat epithelial ovarian, fallopian tube, or primary peritoneal cancer.[L43277] Niraparib was approved by the European Commission on November 16, 2017 [L43742] and by Health Canada on June 27, 2019.[L43747]
Synonyms
Niraparib hydrochloride
Niraparib tosylate
Niraparib tosylate monohydrate
Niraparib
Brand Names
Zejula
Akeega
Indication
Niraparib is indicated for the maintenance treatment of adult patients with advanced or recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in complete or partial response to first-line platinum-based chemotherapy.[L43277, L43742, L43747] In Canada and the US, niraparib is also available in a combination product with [abiraterone], which is indicated with [prednisone] for the treatment of adults with deleterious or suspected deleterious BRCA-mutated (BRCAm) metastatic castration-resistant prostate cancer (mCRPC).[L46896, L47755] In Canada, this combination product is also used with [prednisolone] and is reserved for patients who are asymptomatic or mildly symptomatic, and in whom chemotherapy is not clinically indicated.[L46896]
Categories
Antineoplastic Agents
Antineoplastic and Immunomodulating Agents
BCRP/ABCG2 Inhibitors
BCRP/ABCG2 Substrates
Cytochrome P-450 CYP1A2 Inducers
Cytochrome P-450 CYP1A2 Inducers (weak)
Cytochrome P-450 Enzyme Inducers
Enzyme Inhibitors
Heterocyclic Compounds, Fused-Ring
MATE 1 Inhibitors
MATE 1 Substrates
MATE 1 Substrates with a Narrow Therapeutic Index
MATE 2 Inhibitors
MATE 2 Substrates
MATE 2 Substrates with a Narrow Therapeutic Index
MATE inhibitors
MATE substrates
Narrow Therapeutic Index Drugs
P-glycoprotein substrates
P-glycoprotein substrates with a Narrow Therapeutic Index
Drug Info/Drug Targets: DrugBank 3.0: a comprehensive resource for 'omics' research on drugs. Knox C, Law V, Jewison
T, Liu P, Ly S, Frolkis A, Pon A, Banco K, Mak C, Neveu V, Djoumbou Y, Eisner R, Guo AC, Wishart DS.
Nucleic Acids Res. 2011 Jan; 39 (Database issue):D1035-41. | PMID:21059682
